Navigation Links
First Patient Treated in PLC Systems' RenalGuard® U.S. Pivotal Trial
Date:1/23/2012

se, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2010, a copy of which is on file with the SEC.

PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.

Contact: Mary T. Conway
508-520-2545
mconway@plcmed.com


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... , April 26 e-MDs, an industry leader ... and practice management (PM) solutions, announced they have been selected ... Alaska EHR Alliance (AEHRA).   e-MDs was identified through ... Alaska healthcare providers looking to incorporate an EHR in ...
... 26 Sirion Therapeutics, Inc., a privately held ophthalmic ... is now commercially available.  Zirgan™, which was approved by the ... is a topical ophthalmic antiviral indicated for the treatment of ... , , ...
Cached Medicine Technology:Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 2Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 3Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 4Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:7/10/2014)... as tempting as full-fat equivalents could be heading ... how proteins can replace fats without affecting foodstuffs, ... Engineering and Physical Sciences Research Council (EPSRC), a ... Edinburgh has produced modified proteins that easily break ... behaviour of fats during food manufacture. The proteins ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2
... nutritional supplement used by weightlifters and sprinters to improve ... muscular dystrophies. ,Muscle strength increased by an ... to those who did not use the supplement, according ... gained an average of 1.4 pounds more lean body ...
... promise for people suffering from insomnia, particularly narcolepsy - a ... during waking hours.// ,The first phase of the ... 70 males for about 12 hours, who were healthy and ... ,They found that when orexin, a neuropeptide that ...
... can be used as an oral contraceptive for birth control ... and Drug Administration have formulated this drug especially for woman, ... dysphoric disorders. ,The YAZ drug, manufactured by Bayer ... by the FDA for three distinct uses. ,Phil ...
... life of common man. They are intended to boost the sale ... When it comes to promoting// drugs through commercials, the campaigns are ... don’t need them. ,This was revealed in a survey ... University of California – Los Angeles Department of Medicine. This group ...
... in at least ten districts of Nairobi. This was announced ... Munyao declared that 100,000 doses of vaccines are being distributed ... of insecticides have also been handed over to these places. ... due to RVF and four hundred cases are reported sick. ...
... ,The Canadian Football League linebacker and father of two, ... was infected with HIV while having sexual relationships with two ... with the court, Smith tested HIV positive and was informed ... asked to inform his sexual partners about this and to ...
Cached Medicine News:Health News:Creatine Supplement May Help People With Muscular Dystrophies 2
Mac Pherson titanium tying forceps are ergonomic, very thin, angled with tying platforms. Round ergonomic design for great balance and feel. Fine platforms excellent for tying 10-0 suture....
Fine tying forceps, standard with smooth jaws. For 7-0 to 9-0 sutures....
Harms tying forceps, standard, straight with smooth jaws. For 7-0 to 9-0 sutures....
Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures....
Medicine Products: